Literature DB >> 22177953

MEK1/2 dual-specificity protein kinases: structure and regulation.

Robert Roskoski1.   

Abstract

MEK1 and MEK2 are related protein kinases that participate in the RAS-RAF-MEK-ERK signal transduction cascade. This cascade participates in the regulation of a large variety of processes including apoptosis, cell cycle progression, cell migration, differentiation, metabolism, and proliferation. Moreover, oncogenic mutations in RAS or B-RAF are responsible for a large proportion of human cancers. MEK1 is activated by phosphorylation of S218 and S222 in its activation segment as catalyzed by RAF kinases in an intricate process that involves a KSR scaffold. Besides functioning as a scaffold, the kinase activity of KSR is also required for MEK activation. MEK1 regulation is unusual in that S212 phosphorylation in its activation segment is inhibitory. Moreover, active ERK catalyzes a feedback inhibitory phosphorylation of MEK1 T292 that serves to downregulate the pathway.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22177953     DOI: 10.1016/j.bbrc.2011.11.145

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  83 in total

Review 1.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

2.  Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation.

Authors:  Wei Wu; Mahendra D Chordia; Barry P Hart; E Sathyajith Kumarasinghe; Min K Ji; Ajay Bhargava; Michael W Lawlor; Ji-Yeon Shin; Fusako Sera; Shunichi Homma; Antoine Muchir; Uday R Khire; Howard J Worman
Journal:  Bioorg Med Chem       Date:  2016-12-09       Impact factor: 3.641

Review 3.  Molecular regulation of human skeletal muscle protein synthesis in response to exercise and nutrients: a compass for overcoming age-related anabolic resistance.

Authors:  Nathan Hodson; Daniel W D West; Andrew Philp; Nicholas A Burd; Daniel R Moore
Journal:  Am J Physiol Cell Physiol       Date:  2019-08-28       Impact factor: 4.249

4.  DA-Raf-dependent inhibition of the Ras-ERK signaling pathway in type 2 alveolar epithelial cells controls alveolar formation.

Authors:  Haruko Watanabe-Takano; Kazunori Takano; Akemi Sakamoto; Kenji Matsumoto; Takeshi Tokuhisa; Takeshi Endo; Masahiko Hatano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

5.  Lipin1 Regulates Skeletal Muscle Differentiation through Extracellular Signal-regulated Kinase (ERK) Activation and Cyclin D Complex-regulated Cell Cycle Withdrawal.

Authors:  Weihua Jiang; Jing Zhu; Xun Zhuang; Xiping Zhang; Tao Luo; Karyn A Esser; Hongmei Ren
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

6.  ERK1 is dispensable for mouse pancreatic beta cell function but is necessary for glucose-induced full activation of MSK1 and CREB.

Authors:  Michele Leduc; Joy Richard; Safia Costes; Dany Muller; Annie Varrault; Vincent Compan; Julia Mathieu; Jean-François Tanti; Gilles Pagès; Jacques Pouyssegur; Gyslaine Bertrand; Stéphane Dalle; Magalie A Ravier
Journal:  Diabetologia       Date:  2017-07-18       Impact factor: 10.122

7.  Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation.

Authors:  Jessie Peh; Matthew W Boudreau; Hannah M Smith; Paul J Hergenrother
Journal:  Cell Chem Biol       Date:  2018-06-14       Impact factor: 8.116

8.  Evidence for elevated (LIMK2 and CFL1) and suppressed (ICAM1, EZR, MAP2K2, and NOS3) gene expressions in metabolic syndrome.

Authors:  Suzan Tabur; Serdar Oztuzcu; Elif Oguz; Seniz Demiryürek; Hasan Dagli; Belgin Alasehirli; Mesut Ozkaya; Abdullah T Demiryürek
Journal:  Endocrine       Date:  2016-03-08       Impact factor: 3.633

9.  A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells.

Authors:  Trish T Hoang; I Caglar Tanrikulu; Quinn A Vatland; Trieu M Hoang; Ronald T Raines
Journal:  Mol Cancer Ther       Date:  2018-10-03       Impact factor: 6.261

Review 10.  MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.

Authors:  Pui-Kei Wu; Jong-In Park
Journal:  Semin Oncol       Date:  2015-09-24       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.